Bibliography
- BISCHOFF JR, ANDERSON L, ZHU Y et al.: A homolog of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. (1998) 17:3052-3065.
- WANG X; ZHOU YX, QIAO W et al.: Overexpression of Aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene (2006) 25:7148-7158.
- MORTLOCK AA, KEEN NJ, JUNG FH et al.: Progress in the development of selective inhibitors of Aurora kinases. Curr. Top. Med. Chem. (2005) 5(8):807-821.
- FANCELLI D, MOLL J: Inhibitors of Aurora kinases for the treatment of cancer. Expert Opin. Ther. Patents (2005) 15(9):1169-1182.
- GOLEC JM: Perspectives on the discovery of VX-680, a selective inhibitor of the Aurora kinases. 229th ACS National Meeting, San Diego, CA, USA (2005). MEDI-307.
- HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. (2004) 10(3):262-267.
- FANCELLI D, MOLL J, VARASI M et al.: 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. (2006) 49:7247-7251.
- MANFREDI M, ECSEDY J, MEETZE K et al.: MLN8054, an orally active Aurora-A kinase small molecule inhibitor in Phase I clinical trials. 97th Annual AACR Meeting Washington DC, USA (2006). Abstract 4724.
- FOOTE KM, MORTLOCK AA, HERON NM et al.: The discovery of AZD1152: a novel and highly potent Aurora kinase inhibitor. AACR-NCI- EORTC Int. Conference on Molecular Targets and Cancer Therapeutics Philadelphia PA, USA (2005). Abstract C271.
- WILKINSON RW, KEEN N, ODEDRA R et al.: AZD1152: a highly potent and specific Aurora kinase inhibitor. 97th Annual AACR Meeting. Washington DC, USA (2006). Abstract 5673.
- MATTHEWS N, VISINTIN C, HARTZOULAKIS B et al.: Aurora-A and -B kinases as targets for cancer: will they be selective for tumors? Expert Rev. Anticancer Ther. (2006) 6(1):109-120.
- SHIMAMURA T, SHIBATA J, KURIHARA H et al.: Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, -2, -5, -7 and -9. Bioorg. Med. Chem. Lett. (2006) 16(14):3751-3754.
- FANCELLI D, BERTA D, BINDI S et al.: Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. (2005) 48:3080-3084
- JUNG F, PASQUET G, VAN DER BREMPT CL et al.: Discovery of novel and potent thiazoloquinazolines as selective Aurora-A and -B kinase inhibitors. J. Med. Chem (2006) 49(3):955-970.
Patents
- VERTEX PHARM., INC.: WO04000833 (2003).
- PHARMACIA ITALIA (NERVIANO MEDICAL SCIENCES): WO2005005427 (2005)
- MILLENNIUM PHARM., INC.: US2005256102 (2005)
- ASTRAZENECA: WO04058781 (2004).
- HOFFMAN-LA ROCHE: WO2006108489 (2006).
- HOFFMAN-LA ROCHE: WO2006108488 (2006).
- BANYU: WO2006049339 (2006).
- BANYU: WO2006025567 (2006).
- BANYU: WO2006008874 (2006).
- BANYU: WO2004039809 (2004).
Websites
- http://www.clinicaltrials.gov Clinical trials website.
- http://www.nervianoms.com Nerviano Medical Sciences website.
- http://www.millennium.com/rd/pipeline/ index.asp Millennium R&D pipeline.
- http://www.astrazeneca.com/article/511390. aspx Astrazeneca pipeline summary.
- http://www.rigel.com/rigel/pipeline Rigel pipeline.
- http://www.sunesis.com/pipeline/programs. php Sunesis programs.
- http://www.astex-therapeutics.com/products/clinicalcandidates.php Astex clinical candidates website.